Iloprost
Overview
Iloprost is a synthetic analogue of prostacyclin, used in the treatment of pulmonary arterial hypertension. It works by dilating blood vessels and inhibiting platelet aggregation.
API suppliers (6)
Suppliers of Iloprost evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 5 of 6 suppliers.
1 of 6 holds a GMP certificate on record in the EU or UK registers
- Bayer AGGermany1 active DMF
- EUROAPI HUNGARY LTDHungary1 active DMF
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- YS LIFE SCIENCE CO LTD1 active DMF
- CHIROGATE INTERNATIONAL INCTaiwan1 active DMF
- ScheringUnited Kingdom
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Iloprost expires 18 Jul 2044 and exclusivity 13 Feb 2031. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Iloprost? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.